Sign in Subscribe

crc-research

A collection of 723 issues

BREAKWATER explores molecular markers in BRAF V600E disease

Skip to content The CRC Digest BREAKWATER explores molecular markers in BRAF V600E disease Phase III trial data from ESMO GI examines correlates of response to encorafenib plus cetuximab and chemo. (Oncodaily) This content is informational only and does not constitute medical advice. Always consult your oncologist or care team.

Early-onset CRC shows distinct prognostic factors compared to late-onset disease

Skip to content The CRC Digest Early-onset CRC shows distinct prognostic factors compared to late-onset disease Retrospective study of 1,148 patients (247 under age 50) used machine learning to identify age-specific prognostic factors for overall survival. (PeerJ) This content is informational only and does not constitute medical advice. Always

CRC Research Finding

Skip to content The CRC Digest Dihydroartemisinin targets KRASG12D to overcome immunotherapy resistance Anti-malaria drug selectively downregulates KRASG12D mutant protein and enhances regorafenib plus anti-PD-1 in preclinical liver metastasis models. (Cell Death & Disease) This content is informational only and does not constitute medical advice. Always consult your oncologist or

This Week in CRC Research — July 05, 2026

Weekly colorectal cancer research intelligence

Researchers question whether lymph node removal may impair immunotherapy response

Skip to content The CRC Digest ◇ RESEARCH Researchers question whether lymph node removal may impair immunotherapy response — Colorectal Disease A hypothesis-generating review examines whether routine lymphadenectomy (removal of ≥12 lymph nodes, a well-recognized quality indicator in colorectal cancer surgery) may theoretically impair systemic immune surveillance and immune checkpoint inhibitor (ICI)

CT radiomics identifies imaging biomarkers in RAS-mutant metastatic colorectal cancer

Skip to content The CRC Digest ◇ RESEARCH CT radiomics identifies imaging biomarkers in RAS-mutant metastatic colorectal cancer — European Journal of Radiology Researchers established a co-clinical computed tomography (CT) radiomics pipeline for identifying candidate imaging biomarkers in RAS-mutant metastatic colorectal cancer. Orthotopic KRAS-mutant xenograft models (LOVO-Luc2 and SW480-Luc2, N=52 each)

Irisin enhances 5-fluorouracil effectiveness in colon cancer cells

Skip to content The CRC Digest ◇ RESEARCH Irisin enhances 5-fluorouracil effectiveness in colon cancer cells — International Journal of Applied and Basic Medical Research Human HT-29 CRC cells were treated for 12 hours with irisin (2, 20, and 200 ng/mL) alone or combined with 5-FU (50 μM). Cell cycle progression

Scientists identify metabolic pathway driving cetuximab resistance

Skip to content The CRC Digest ◇ RESEARCH Scientists identify metabolic pathway driving cetuximab resistance — Cell Death & Disease Researchers discovered that glutamate dehydrogenase 1 (GDH1) accumulation drives cetuximab resistance in metastatic colorectal cancer. When cetuximab blocks EGFR, it prevents phosphorylation of GDH1, leading to its accumulation and increased production of

Alpelisib plus capecitabine shows modest activity in PIK3CA-mutant metastatic colorectal cancer

Skip to content The CRC Digest ◆ TRIAL DATA Alpelisib plus capecitabine shows modest activity in PIK3CA-mutant metastatic colorectal cancer — Scientific Reports A phase 2 study tested alpelisib (a PI3K inhibitor) combined with capecitabine in 26 patients with PIK3CA-mutant metastatic colorectal cancer who had progressed after standard chemotherapy. The trial was

Re-challenging BRAF V600E tumors with encorafenib, cetuximab, and nivolumab shows success

Skip to content The CRC Digest ▸ TREATMENT Re-challenging BRAF V600E tumors with encorafenib, cetuximab, and nivolumab shows success — Clinical Colorectal Cancer A case report from the AGMT mCRC Registry documented successful re-challenge with encorafenib and cetuximab combined with nivolumab in a patient with BRAF V600E mutated, mismatch-repair-proficient (pMMR) metastatic colorectal